Table 2.
Subject characteristics and islet morphometric analyses in individuals with CF, subdivided according to diabetes and lung transplant status
| CF-no DM |
CFRD |
||||
|---|---|---|---|---|---|
| No lung transplant | Lung transplant | No lung transplant | Lung transplant | ||
| N | 13 | 4 | 6 | 10 | |
| Age (years) | 11.9 ± 2.4 | 20.3 ± 1.0 | 22.8 ± 3.4 | 31.4 ± 2.8 | |
| Sex (female/male) | 11/2 | 1/3 | 3/3 | 6/4 | |
| BMI (kg/m2) | 15.2 ± 0.6 | 20.3 ± 2.8 | 21.9 ± 1.3 | 22.0 ± 1.2 | |
| Diabetes duration (years) | — | — | 6.6 ± 3.1 | 4.2 ± 1.0 | |
| HbA1c (%) (n = 4–6) | — | — | 7.8 ± 0.9 | 6.5 ± 0.4 | |
| Subjects with islet IL-1β, n (%) | 11 (91) | 2 (50) | 6 (100) | 8 (80) | |
| IL-1β–positive islets (%) | 28.8 ± 8.5 | 31.1 ± 18.8 | 63.5 ± 9.5 | 61.8 ± 12.3 | |
| Subjects with islet amyloid, n (%) | 2 (11) | 1 (25) | 3 (50) | 7 (70) | |
| Amyloid-positive islets (%) | 3.3 ± 3.2 | 0.3 ± 0.3 | 5.2 ± 3.2 | 31.0 ± 12.2 | |
| Insulin-positive area (%) | 1.5 ± 0.3 | 2.8 ± 0.9 | 1.1 ± 0.4 | 1.3 ± 0.2 | |
| Glucagon-positive area (%) | 1.2 ± 0.3 | 3.5 ± 0.6 | 1.5 ± 0.5 | 2.5 ± 0.7 | |
| Somatostatin-positive area (%) (n = 8, 3, 4, and 5, respectively) | 0.5 ± 0.1 | 0.6 ± 0.2 | 0.2 ± 0.1 | 0.7 ± 0.3 | |
| PP-positive area (%) (n = 8, 3, 4, and 5, respectively) | 0.6 ± 0.1 | 0.1 ± 0.1* | 0.2 ± 0.1 | 0.2 ± 0.1 | |
Data are mean ± SEM or n unless otherwise indicated.
*P < 0.05 vs. CF-no DM, no transplant group.